RESUMEN
In the present study, anti-proliferative effects of dietary polyphenolic compounds have been observed and demonstrated the strong anticancer efficacy of curcumin (CMN), an active constituent of dietary spice (turmeric) using human leukemia cancer cell line. CMN inhibited the proliferation of K562 leukemic cells by induction of apoptosis. The current study demonstrated synergy with combination of drug therapy, and suggested that combination of ferulic acid and cisplatin synergistically inhibited cellular proliferation. Cytotoxic synergy was observed independent of the sequence of addition of two drugs to cultured cells. The synergized growth inhibitory effect with cisplatin was probably associated with G2-M arrest in cell cycle progression. These findings suggested that among the cinnamoyl compounds, CMN was most potent and FER appeared to be a better modulating agent on human malignant cell line.
Asunto(s)
Antineoplásicos/química , Antineoplásicos/farmacología , Ciclo Celular/efectos de los fármacos , Curcuma/química , Curcumina/química , Curcumina/farmacología , Leucemia Eritroblástica Aguda/patología , Proliferación Celular/efectos de los fármacos , Cisplatino/química , Cisplatino/farmacología , Ciclodextrinas/química , Ciclodextrinas/farmacología , Flavonoides/química , Flavonoides/farmacología , Humanos , Células K562 , Fenoles/química , Fenoles/farmacología , PolifenolesRESUMEN
N-(o-methoxyphenyl)-maleimide (I), an intermediate obtained during the synthesis of pyrrolidinedione-N-mustards, did not exhibit antitumor activity against Ehrlich (ascites) carcinoma. The effect of co-administration of (I), with established anticancer drugs was studied against P388 leukemia, S180 (ascites) and Ehrlich (ascites) carcinoma. A significant potentiation in the activity of 5-Fluorouracil (5-FU) against Ehrlich (ascites) carcinoma by (I) was observed. The possible mechanisms responsible for potentiation of the activity of 5-FU are presented.
Asunto(s)
Antineoplásicos/uso terapéutico , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Carcinoma de Ehrlich/tratamiento farmacológico , Fluorouracilo/uso terapéutico , Maleimidas/toxicidad , Animales , Ciclofosfamida/administración & dosificación , Ciclofosfamida/uso terapéutico , Citarabina/administración & dosificación , Citarabina/uso terapéutico , Fluorouracilo/administración & dosificación , Maleimidas/administración & dosificación , Mecloretamina/administración & dosificación , Mecloretamina/uso terapéutico , Mercaptopurina/administración & dosificación , Mercaptopurina/uso terapéutico , Ratones , Mitomicina , Mitomicinas/administración & dosificación , Mitomicinas/uso terapéutico , Vinblastina/administración & dosificación , Vinblastina/uso terapéuticoRESUMEN
alpha-[N,N-[bis(2-hydroxyethyl)]-amino]-N- (o-methoxyphenyl)pyrrolidin-2,5-dione (I), an intermediate in the synthesis of pyrrolidinedione-N-mustards, did not exhibit antitumour activity against P388 lymphocytic leukemia, Sarcoma 180 (ascites) and Ehrlich (ascites) carcinoma tumours. The effect of co-administration of (I) with established anticancer drugs was studied against these murine tumours. The activity of 5-fluorouracil against Sarcoma 180 (ascites) and Ehrlich (ascites) carcinoma was significantly enhanced by co-administration with (I). Other anticancer drugs, when co-administered with (I), did not show any enhancing effect.
Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/farmacología , Carcinoma de Ehrlich/tratamiento farmacológico , Leucemia P388/tratamiento farmacológico , Leucemia Experimental/tratamiento farmacológico , Compuestos de Mostaza Nitrogenada/farmacología , Pirrolidinonas/farmacología , Sarcoma 180/tratamiento farmacológico , Animales , Sinergismo Farmacológico , Femenino , Fluorouracilo/farmacología , Masculino , RatonesRESUMEN
(R,S)3-(N,N-[bis-(2-chloroethyl)]-amino)-1-(2'-methoxyphenyl)- pyrrolidine-2,5-dione hydrochloride (I) has shown antitumor activity against P388 and L1210 leukaemias and Sarcoma 180 (ascites). The effect of (I), when co-administered with anticancer drugs, was studied in these murine tumours. Although co-administration of (I) with methotrexate showed a significant increase of the activity against P388 and L1210 leukaemias and Sarcoma 180 (ascites), co-administration of (I) with 5-fluorouracil, mitomycin C, adriamycin or vincristine did not exhibit any enhancing, synergistic or additive effect in the activity of these drugs.
Asunto(s)
Antineoplásicos/administración & dosificación , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Neoplasias Experimentales/tratamiento farmacológico , Compuestos de Mostaza Nitrogenada/administración & dosificación , Pirrolidinonas/administración & dosificación , Animales , Sinergismo Farmacológico , Femenino , Masculino , Ratones , Ratones EndogámicosRESUMEN
The ways by which cell death takes place have generated great interest in recent years particularly in the field of cancer. The exact mechanisms which are responsible for tumour regression by drug treatment are also largely unknown and involve both enhanced cell death and arrested cell proliferation. Cell death is caused either by necrosis or by an active process in response to a specific stimulus which leads to elimination of a definite proportion of cells. This process of programmed cell death is referred to as apoptosis (a term coined by developmental biologists) and is a part of the morphogenetic processes, characterized by shrinkage of cells, condensation of nuclear chromatin, nuclear fragmentation and blebbing. Many successful cancer treatments presently undertaken depend upon induction of an apoptotic response in the target tumour cells. As apoptosis is considered to be an active gene-directed process, in tumours the precise mode of cell death after chemotherapy is important. Understanding the role of apoptosis in cancer will greatly broaden our knowledge of all stages of the disease process and its treatment. Thus, the role of apoptotic response modulation during the generation of neoplasia is an important issue and will remain an active area of present day investigations for improving the efficiency of chemotherapy. It is likely to become a valuable weapon in the war against cancer.
Asunto(s)
Antineoplásicos/uso terapéutico , Apoptosis/efectos de los fármacos , Supervivencia Celular/efectos de los fármacos , Neoplasias/tratamiento farmacológico , División Celular/efectos de los fármacos , Daño del ADN , Humanos , Células Tumorales Cultivadas/efectos de los fármacosRESUMEN
The anti-tumour effects of methoxyphenyl maleamic acid (MPMA) and cytotoxic drugs, in combination were investigated on P388 leukaemia and S180 (ascites) tumours. Simultaneous administration of MPMA with CTX or HN2 resulted in enhancement of anti-tumour activity. The increased activity was observed against P388 leukaemia, whereas S180 (ascites) tumour was not responsive to the combined treatment. The possible mechanism (s) of action, responsible for the modulation of activity of CTX and HN2 against P388 tumour have been postulated.
Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Leucemia P388/tratamiento farmacológico , Maleatos/farmacología , Animales , Ascitis/tratamiento farmacológico , Ciclofosfamida/administración & dosificación , Sinergismo Farmacológico , Mecloretamina/administración & dosificación , RatonesRESUMEN
The ability of the differentiation inducing agent sodium butyrate (NaB) alone or combined with plant-derived phenolic compounds to produce growth inhibition in human erythroleukemic cells was investigated. As a single agent, curcumin produced a marked inhibition of proliferation indicated by its low concentration used. The effect of phenolics on the cell cycle could probably contribute to the augmented antiproliferative activity of NaB. The present data show that quercetin produced synergistic effect in terms of cell killing in association with NaB. Both curcumin and ferulic acid potentiated NaB-induced reduction of cell number. When NaB was added before exposure to graded doses of quercetin it did induce a greater inhibitory effect. The combination of NaB and quercetin seems less effective on S180 ascites tumour cells. As a single agent quercetin was found to be the most efficacious on S180 tumour model.
Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Butiratos/farmacología , Ácidos Cumáricos/farmacología , Curcumina/farmacología , Quercetina/farmacología , Sarcoma 180/tratamiento farmacológico , Animales , Butiratos/administración & dosificación , División Celular/efectos de los fármacos , Supervivencia Celular/efectos de los fármacos , Ácidos Cumáricos/administración & dosificación , Curcumina/administración & dosificación , Sinergismo Farmacológico , Citometría de Flujo , Humanos , Células K562 , Ratones , Trasplante de Neoplasias , Quercetina/administración & dosificación , Sarcoma 180/patologíaRESUMEN
The combined effect of cyclophosphamide (CTX) and extracts of six patients belonging to Crotalaria and Senecio genera was assessed on experimental transplantable S180 (both ascitic and solid forms) tumour. Successive petroleum ether and methanolic extracts from these plants were obtained. The combined administration of CTX and petroleum ether extract of C. albida and the methanolic extracts of C. albida, S. chrysanthemoides, S. densiflorus and S. jacquemontianus led to prolonging the life span of S180 (ascitic) tumour bearing mice. The data indicate that the most effective extract in combination with CTX was the methanolic extract of S. chrysanthemoides. The extracts alone had no effect on survival of tumour-bearing mice. The same extracts and the same combinations had no effect on S180 solid tumour.
Asunto(s)
Antineoplásicos Fitogénicos/administración & dosificación , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Ciclofosfamida/administración & dosificación , Fitoterapia , Extractos Vegetales/administración & dosificación , Sarcoma 180/tratamiento farmacológico , Animales , Ratones , Trasplante de Neoplasias , Plantas Tóxicas , SenecioRESUMEN
Semecarpus anacardium Linn.f. nuts were extracted by using non-polar and polar organic solvents. Hot methanol extract and a resinous fraction, isolated from it, showed antitumour activity against P388 lymphocytic leukaemia in BDF1 mice as judged by their median survival time. Petroleum ether extract and its chromatographically isolated fraction were obtained. The latter fraction was distilled under reduced pressure to get an orange-coloured oil, (b.p. 200-20 degrees/2-3 mm). Both had antitumour activity. The orange-coloured oil, on further distillation under reduced pressure, yielded Bhilawanol. An acetyl derivative of the oil was also obtained. The latter two also had antitumour activity.
Asunto(s)
Antineoplásicos Fitogénicos , Aceites/farmacología , Animales , Leucemia L1210/tratamiento farmacológico , Leucemia P388/tratamiento farmacológico , Ratones , Extractos Vegetales/farmacologíaRESUMEN
The cytotoxic effects of acetylated oil of Semecarpus anacardium nuts on the cells of P388 lymphocytic leukemia were tested in vitro. The product was tested at the concentrations ranging from 15-75 micrograms/ml. The cell kill was observed as early as three hr after the treatment. The effects of acetylated oil on the biosynthesis of DNA, RNA and protein using labelled thymidine, uridine and leucine respectively showed that the product inhibited the biosynthesis of all the three. This was indicated by the inhibition of the incorporation of their precursors. The uptake of 3H-thymidine was inhibited 15 min after treatment; while that of 3H-uridine and 14C-leucine took 30 and 45 min respectively. Since the S. anacardium oil was unstable due to air-oxidation, the studies were confined to its acetylated product.
Asunto(s)
Antineoplásicos Fitogénicos , Aceites/farmacología , Acetilación , Animales , ADN de Neoplasias/metabolismo , Femenino , India , Leucemia P388/tratamiento farmacológico , Masculino , Ratones , Ratones Endogámicos DBA , Proteínas de Neoplasias/metabolismo , ARN Neoplásico/metabolismo , Factores de TiempoRESUMEN
BACKGROUND: Turmeric (Curcuma longa) has been shown to possess anti-inflammatory, antioxidant and antitumor properties. However, despite the progress in research with C. longa, there is still a big lacuna in the information on the active principles and their molecular targets. More particularly very little is known about the role of cell cycle genes p57(kip2) and Rad9 during chemoprevention by turmeric and its derivatives especially in prostate cancer cell lines. METHODS: Accordingly, in this study, we have examined the antitumor effect of several extracts of C. longa rhizomes by successive fractionation in clonogenic assays using highly metastatic PC-3M prostate cancer cell line. RESULTS: A mixture of isopropyl alcohol: acetone: water: chloroform: and methanol extract of C. longa showed significant bioactivity. Further partition of this extract showed that bioactivity resides in the dichloromethane soluble fraction. Column chromatography of this fraction showed presence of biological activity only in ethyl acetate eluted fraction. HPLC, UV-Vis and Mass spectra studies showed presence three curcuminoids in this fraction besides few unidentified components. CONCLUSIONS: From these observations it was concluded that the ethyl acetate fraction showed not only inhibition of colony forming ability of PC-3M cells but also up-regulated cell cycle genes p57(kip2) and Rad9 and further reduced the migration and invasive ability of prostate cancer cells.
Asunto(s)
Proteínas de Ciclo Celular/metabolismo , Curcuma , Inhibidor p57 de las Quinasas Dependientes de la Ciclina/metabolismo , Extractos Vegetales/farmacología , Neoplasias de la Próstata/prevención & control , Antioxidantes/farmacología , Línea Celular Tumoral , Proliferación Celular/efectos de los fármacos , Fraccionamiento Químico , Humanos , Masculino , Invasividad Neoplásica , Fitoterapia , Extractos Vegetales/uso terapéutico , Neoplasias de la Próstata/tratamiento farmacológicoRESUMEN
Combination chemotherapy studies were carried out in vivo against sarcoma 180 (ascites)(S180) and Ehrlich (ascites) carcinoma (EAC) tumours using cytotoxic drugs and methoxyphenyl maleamic acid (MPMA), an intermediate in the synthesis of pyrrolidine-nitrogen-mustards. Preliminary data have suggested that the combination of 5-fluorouracil (5-FU) and methoxyphenyl maleamic acid (MPMA) was more active than 5-FU used singly against EAC tumour. The possible therapeutic potential of this combination was further investigated in EAC tumour.
Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Carcinoma de Ehrlich/tratamiento farmacológico , Fluorouracilo/administración & dosificación , Maleatos/administración & dosificación , Sarcoma 180/tratamiento farmacológico , Animales , Quimioterapia Combinada , Femenino , Masculino , Ratones , Distribución AleatoriaRESUMEN
The anti-tumor effect of 3-amino-N-substituted pyrrolidine-2,5-dione-N-mustard hydrochloride (PNM.HCl) against Ehrlich (ascites) carcinoma (EAC) was studied. A substantial increase in the survival of mice bearing EAC tumor was achieved following daily administration of PNM.HCl at subtoxic dosages. The therapeutic efficacy of PNM.HCl was maintained with changes in dosages and the schedules of administration. The effect of PNM.HCl when administered with conventional anti-cancer drugs at different time schedules against EAC was also studied. The results demonstrated an augmentation of anti-tumor activity in the case of certain anti-cancer drugs against EAC tumor, thereby suggesting a potential usefulness of PNM.HCl in multi-drug therapy.